People: POZEN Inc (POZN.O)
POZN.O on Nasdaq
5.03USD
9:49am EDT
5.03USD
9:49am EDT
Price Change (% chg)
$0.07 (+1.41%)
$0.07 (+1.41%)
Prev Close
$4.90
$4.90
Open
$5.00
$5.00
Day's High
$5.08
$5.08
Day's Low
$5.00
$5.00
Volume
15,976
15,976
Avg. Vol
271,074
271,074
52-wk High
$7.55
$7.55
52-wk Low
$4.26
$4.26
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
John Plachetka |
59 | 2001 | Chairman of the Board, President, Chief Executive Officer |
William Hodges |
58 | 2004 | Chief Financial Officer, Senior Vice President - Finance and Administration |
Elizabeth Cermak |
55 | 2009 | Executive Vice President, Chief Commercial Officer |
Gilda Thomas |
58 | 2007 | Senior Vice President, General Counsel |
John Barnhardt |
63 | 2012 | Vice President - Finance and Administration |
John Fort |
58 | 2007 | Chief Medical Officer |
Kenneth Lee |
64 | 2005 | Lead Independent Director |
Neal Fowler |
49 | 2010 | Independent Director |
Arthur Kirsch |
60 | 2004 | Independent Director |
Martin Nicklasson |
58 | 2011 | Independent Director |
Jacques Rejeange |
73 | 2007 | Independent Director |
Seth Rudnick |
63 | 2011 | Independent Director |
Biographies
| Name | Description |
|---|---|
John Plachetka |
Dr. John R. Plachetka, Pharm.D., is Chairman of the Board, President, Chief Executive Officer of Pozen Inc. Prior to founding POZEN, Dr. Plachetka was Vice President of Development at Texas Biotechnology Corporation from 1993 to 1995 and was President and Chief Executive Officer of Clinical Research Foundation-America, clinical research organization, from 1990 to 1992. From 1981 to 1990, he was employed at Glaxo Inc. Dr. Plachetka received his B.S. in Pharmacy from the University of Illinois College of Pharmacy and his Doctor of Pharmacy from the University of Missouri-Kansas City. |
William Hodges |
Mr. William L. Hodges, CPA, is Chief Financial Officer, Senior Vice President - Finance and Administration of Pozen Inc. Mr. Hodges began his career in the pharmaceutical industry with Burroughs Wellcome Co. in 1985. In 1991, he moved to London and worked in Group Finance for the Wellcome Foundation, Ltd. Mr. Hodges worked on mergers and acquisitions and was Regional Controller for Northern Europe and Japan. In 1993, he returned to Burroughs Wellcome in North Carolina as Director of Procurement. Mr. Hodges was Vice President, Corporate Planning and Business Support at GlaxoWellcome before being appointed acting Senior Vice President and CFO for the fifteen months up to the merger between GlaxoWellcome plc and SmithKline Beecham plc which was completed in December of 2000. Prior to joining POZEN, Mr. Hodges was Senior Vice President and CFO of Pergo, Inc. located in Raleigh, North Carolina. Mr. Hodges received his B.S. from the University of North Carolina at Chapel Hill and is a Certified Public Accountant. |
Elizabeth Cermak |
Ms. Elizabeth A. Cermak, MBA, is Executive Vice President, Chief Commercial Officer of Pozen Inc. Prior to joining POZEN, Ms. Cermak was Worldwide Vice President in the Consumer Health Division of Johnson and Johnson from 2006. From 2005, she was Vice President Business Development for McNeil Consumer and Specialty, Inc. and from 2003 to 2005 was Vice President, Women’s Health Franchise at Ortho-McNeil Pharmaceuticals, Inc. She has spent over 25 years in the healthcare industry and has led a number of marketing and sales organizations. Ms. Cermak holds an MBA in Finance from Drexel University in Philadelphia, PA, and a BA Cum Laude in Accounting and Spanish from Franklin and Marshall College in Lancaster, PA. |
Gilda Thomas |
Ms. Gilda M. Thomas, JD., is Senior Vice President and General Counsel of Pozen Inc. Prior to joining POZEN, Ms. Thomas was Vice President, General Counsel and company secretary at EMD Pharmaceuticals, Inc., an affiliate of Merck KGaA, Darmstadt, Germany from July 2001 to December 2006. Prior to joining EMD, she spent 14 years at Burroughs Wellcome Co., which merged into Glaxo Welcome, Inc. At Glaxo Wellcome Ms. Thomas was Associate General Counsel responsible for the 13 member corporate section of the legal department. Ms. Thomas received her J.D. from Harvard Law School, a M.S. from Simmons College and a B.A. degree from Wellesley College. |
John Barnhardt |
Mr. John E. Barnhardt, CPA, is Vice President - Finance and Administration of Pozen Inc. Prior to joining POZEN, Mr. Barnhardt held finance and accounting positions with publicly traded companies beginning in 1988. These positions included Chief Financial Officer of Medco Research, Inc., engaged in the research and development of pharmaceutical products primarily for the diagnosis and treatment of cardiovascular disease, and Principal Accounting Officer of Microwave Laboratories, Inc., a defense contractor developing and manufacturing traveling wave tubes for electronic countermeasure systems. Mr. Barnhardt received his B.S. in Zoology from North Carolina State University, and while employed at Ernst & Young, became a Certified Public Accountant. |
John Fort |
Dr. John G. Fort, M.D., MBA, is Chief Medical Officer of Pozen Inc. Prior to joining POZEN, Dr. Fort was Vice President, Medical Affairs at Adolor Corporation from 2004 until 2007. Dr. Fort held positions with Pfizer Inc., including Vice President, Medical Affairs, and was Vice President, Arthritis and Pain at G.D. Searle & Co., Monsanto Corporation from September 1994 to December 2003. Prior to joining the pharmaceutical industry, he was an Associate Professor of Medicine at Thomas Jefferson University, Division of Rheumatology. Dr. Fort received his M.D. from the University of Valencia Faculty of Medicine and is board certified in internal medicine with a subspecialty certification in rheumatology. |
Kenneth Lee |
Mr. Kenneth B. Lee, Jr., is Lead Independent Director of Pozen Inc., since 2005. He is Independent consultant since June 2002 and general partner of Hatteras Venture Partners (formerly Hatteras BioCapital. LLC and BioVista Capital, LLC), the general partner of Hatteras BioCapital Fund, L.P., a venture capital fund focusing on life sciences companies, since 2003; President of A.M. Pappas & Associates, a venture capital firm, between January 2002 and June 2002. Partner of Ernst & Young LLP from 1982 through 2000; Partner of Ernst & Young Corporate Finance LLC from 2000 to 2001; Managing Director of Ernst & Young’s Health Sciences Corporate Finance Group from 2000 to 2001. He Serves on the boards of the following public companies: Maxygen, Inc., for which he serves as chairman of the audit committee and a member of the nominating/governance committee and the compensation committee, and Biocryst Pharmaceuticals, Inc., for which he serves on the audit committee and finance committee. Previously, he served on the boards of CV Therapeutics, Inc., for which he served as lead independent director and chair of the audit committee, Abgenix, Inc., for which he served on the audit committee and the compensation committee, OSI Pharmaceuticals, for which he served as a member of the audit committee and Inspire Pharmaceuticals Inc., for which he served as chairman of the board of directors, chair of the audit committee and a member of the compensation committee and finance committee. He Serves as a member of the executive committee of the Board of the North Carolina Biotechnology Industry Organization and as a member of the board of Ibiliti, a nonprofit organization dedicated to building and expanding networks of resources for advanced medical technology companies. |
Neal Fowler |
Mr. Neal F. Fowler is an Independent Director of Pozen Inc. He is Chief Executive Officer of Liquidia Technologies, Inc., a privately held biotechnology company since 2008. President of Centocor, Inc., a subsidiary of Johnson & Johnson from 2006 to 2008. President of Ortho-McNeil Neurologics, Inc., a subsidiary of Johnson & Johnson from 2004 to 2006 and Franchise Vice President-CNS from 2001 to 2004. Held various positions at Eli Lilly and Company from 1988 to 2001, including Area Director, Primary Care Division (2001), Director U.S. Cardiovascular Business Unit (1997 to 2000), Cardiovascular Product Manager (1996 to 1997), Operations Manager, Southwest Area (1995), Manager Medical Device and Diagnostics (1993 to 1995), Associate, Marketing Plans, Endocrinology (1992), Associate, Business Development/New Product Planning, Oncology (1990 to 1991), and Retail Sales Representative (1988 to 1990). |
Arthur Kirsch |
Mr. Arthur S. Kirsch is an Independent Director of Pozen Inc. He is Senior Advisor, GCASavvian, LLC (formerly Perseus Group, LLC), an investment bank, since June 2005. Founding member and Managing Director of Vector Securities, LLC, an investment and merchant banking firm, from 2001 to May 2005. Managing Director and Head of Healthcare Research and Capital Markets of Prudential Vector Healthcare Group, a unit of Prudential Securities, Inc., a full-service brokerage firm, from 1999 to 2001. Director, Equity Research of Vector Securities International, Inc., an investment banking firm, from 1995 to 1999. Serves as a director of PhysioSonics, Inc., a privately held company developing noninvasive neurological products. |
Martin Nicklasson |
Dr. Martin Nicklasson is Independent Director of Pozen Inc. Dr. Nicklasson is Senior Partner at Nicklasson Life Science AB, an independent consultancy and advisory company to the pharmaceutical and biotechnology sector since 2011. President and Chief Executive Officer of Biovitrum AB and Swedish Orphan Biovitrum AB, a publicly listed specialty pharma company, from 2007 to 2010. Held various executive vice president positions at AstraZeneca Plc. from 1999 to 2007, including Chairman of the Board of Astra Tech AB, a subsidiary of AstraZeneca (2004 to 2007), Executive Vice President, Global Marketing & Business Development (2005 to 2007), Executive Vice President, Global Drug Development (2002 to 2005) and Executive Vice President, Global Gastrointestinal Franchise (1999 to 2002). Serves as Chairman of the Board of Farma Holdings AS and Orexo AB and serves on the Board of Oasmia AB, Denator AB, Biocrine AB and Heart and Lung Foundation of Sweden. |
Jacques Rejeange |
Mr. Jacques F. Rejeange is no longer Independent Director of Pozen Inc., effective June 6, 2013. He is Retired since 2005. President of Florham Consulting S.A., a healthcare consulting company based in Areuse, Switzerland, from 1995 to 2005. Served as member of board of directors of POZEN from 1997 to 2004 (Chairman from 1999 to 2000); retired from the Board in 2004. Formerly served on the boards of Amersham PLC (UK), Swiss Red Cross Foundation (CH) and NMY AG (CH), a privately held biotechnology company. |
Seth Rudnick |
Dr. Seth A. Rudnick, M.D., is Independent Director of Pozen Inc., since July 25, 2011. He is a Venture partner and previously general partner at Canaan Partners, a venture capital firm, since 1998. Formerly, Chief Executive Officer and Chairman of CytoTherapeutics Inc., a company developing stem cell-based therapies. Helped found and served as the Head of Research and Development for Ortho Biotech, a division of Johnson & Johnson focusing on cancer and chronic illnesses from 1991 to 1998. Serves of the Boards of the following privately held biotechnology companies: Chimerix, Inc., Liquidia Technologies, Inc., ORTHOCON, Inc., Spine Wave, Inc. and VaxInnate, Inc. Currently a Clinical Adjunct Professor of Medicine at University of North Carolina, Chapel Hill. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
John Plachetka |
2,934,660 |
William Hodges |
726,344 |
Elizabeth Cermak |
711,821 |
Gilda Thomas |
583,416 |
John Barnhardt |
623,095 |
John Fort |
726,998 |
Kenneth Lee |
-- |
Neal Fowler |
-- |
Arthur Kirsch |
-- |
Martin Nicklasson |
-- |
Jacques Rejeange |
-- |
Seth Rudnick |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
John Plachetka |
980,322 | 2,719,130 |
William Hodges |
146,645 | 429,367 |
Elizabeth Cermak |
0 | 0 |
Gilda Thomas |
0 | 0 |
John Barnhardt |
226,853 | 1,140,353 |
John Fort |
0 | 0 |
Kenneth Lee |
0 | 0 |
Neal Fowler |
0 | 0 |
Arthur Kirsch |
0 | 0 |
Martin Nicklasson |
0 | 0 |
Jacques Rejeange |
0 | 0 |
Seth Rudnick |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
PLACHETKA JOHN R |
5,340 | $0.00 |
PLACHETKA JOHN R |
5,340 | $0.00 |
HODGES WILLIAM L |
20,000 | $0.00 |
FORT JOHN G |
20,000 | $0.00 |
THOMAS GILDA MARIE |
20,000 | $0.00 |
CERMAK ELIZABETH A |
20,000 | $0.00 |
PLACHETKA JOHN R |
70,016 | $0.00 |
BARNHARDT JOHN ELLIOTT |
12,000 | $0.00 |
HODGES WILLIAM L |
2,000 | $0.00 |
BARNHARDT JOHN ELLIOTT |
5,219 | $5.25 |
BARNHARDT JOHN ELLIOTT |
5,219 | $5.18 |
FORT JOHN G |
21,000 | $0.00 |
BARNHARDT JOHN ELLIOTT |
8,400 | $0.00 |
CERMAK ELIZABETH A |
21,000 | $0.00 |
PLACHETKA JOHN R |
21,000 | $0.00 |
THOMAS GILDA MARIE |
21,000 | $0.00 |
HODGES WILLIAM L |
21,000 | $0.00 |
PLACHETKA JOHN R |
15,000 | $0.00 |
LEE KENNETH B JR |
20,000 | $5.18 |
LEE KENNETH B JR |
1,667 | $5.15 |
LEE KENNETH B JR |
15,871 | $6.49 |
PLACHETKA JOHN R |
45,000 | $6.04 |
PLACHETKA JOHN R |
73,851 | $6.13 |
PLACHETKA JOHN R |
68,649 | $6.29 |
PLACHETKA JOHN R |
187,500 | $5.18 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
